Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma

K.A. Frerichs; M.C. Minnema; M.D. Levin; A. Broijl; G.M.J. Bos; M.J. Kersten; T. Mutis; C.P.M. Verkleij; I.S. Nijhof; P.W.C. Maas-Bosman; S.K. Klein; S. Zweegman; P. Sonneveld; N.W.C.J. van de Donk

doi:10.1182/bloodadvances.2021005220

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma

K.A. Frerichs, M.C. Minnema, M.D. Levin, A. Broijl, G.M.J. Bos, M.J. Kersten, T. Mutis, C.P.M. Verkleij, I.S. Nijhof, P.W.C. Maas-Bosman, S.K. Klein, S. Zweegman, P. Sonneveld, N.W.C.J. van de Donk^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Web of Science)

Original language	English
Pages (from-to)	5128-5139
Number of pages	12
Journal	Blood advances
Volume	5
Issue number	23
DOIs	https://doi.org/10.1182/bloodadvances.2021005220
Publication status	Published - 14 Dec 2021

Keywords

CD38 EXPRESSION
OPEN-LABEL
INTRAVENOUS DARATUMUMAB
UP-REGULATION
CELLS
DEXAMETHASONE
LENALIDOMIDE
MONOTHERAPY
BORTEZOMIB
EXPANSION

Access to Document

10.1182/bloodadvances.2021005220Licence: CC BY-NC-ND

Cite this

Frerichs, K. A., Minnema, M. C., Levin, M. D., Broijl, A., Bos, G. M. J., Kersten, M. J., Mutis, T., Verkleij, C. P. M., Nijhof, I. S., Maas-Bosman, P. W. C., Klein, S. K., Zweegman, S., Sonneveld, P., & van de Donk, N. W. C. J. (2021). Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. Blood advances, 5(23), 5128-5139. https://doi.org/10.1182/bloodadvances.2021005220

Frerichs, K.A. ; Minnema, M.C. ; Levin, M.D. ; Broijl, A. ; Bos, G.M.J. ; Kersten, M.J. ; Mutis, T. ; Verkleij, C.P.M. ; Nijhof, I.S. ; Maas-Bosman, P.W.C. ; Klein, S.K. ; Zweegman, S. ; Sonneveld, P. ; van de Donk, N.W.C.J. / Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. In: Blood advances. 2021 ; Vol. 5, No. 23. pp. 5128-5139.

@article{c3606b53d7894f489b366eac2bcf0b1f,

title = "Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma",

keywords = "CD38 EXPRESSION, OPEN-LABEL, INTRAVENOUS DARATUMUMAB, UP-REGULATION, CELLS, DEXAMETHASONE, LENALIDOMIDE, MONOTHERAPY, BORTEZOMIB, EXPANSION",

author = "K.A. Frerichs and M.C. Minnema and M.D. Levin and A. Broijl and G.M.J. Bos and M.J. Kersten and T. Mutis and C.P.M. Verkleij and I.S. Nijhof and P.W.C. Maas-Bosman and S.K. Klein and S. Zweegman and P. Sonneveld and {van de Donk}, N.W.C.J.",

year = "2021",

month = dec,

day = "14",

doi = "10.1182/bloodadvances.2021005220",

language = "English",

volume = "5",

pages = "5128--5139",

journal = "Blood advances",

issn = "2473-9529",

publisher = "The American Society of Hematology",

number = "23",

}

Frerichs, KA, Minnema, MC, Levin, MD, Broijl, A, Bos, GMJ, Kersten, MJ, Mutis, T, Verkleij, CPM, Nijhof, IS, Maas-Bosman, PWC, Klein, SK, Zweegman, S, Sonneveld, P & van de Donk, NWCJ 2021, 'Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma', Blood advances, vol. 5, no. 23, pp. 5128-5139. https://doi.org/10.1182/bloodadvances.2021005220

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. / Frerichs, K.A.; Minnema, M.C.; Levin, M.D.; Broijl, A.; Bos, G.M.J.; Kersten, M.J.; Mutis, T.; Verkleij, C.P.M.; Nijhof, I.S.; Maas-Bosman, P.W.C.; Klein, S.K.; Zweegman, S.; Sonneveld, P.; van de Donk, N.W.C.J.

In: Blood advances, Vol. 5, No. 23, 14.12.2021, p. 5128-5139.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma

AU - Frerichs, K.A.

AU - Minnema, M.C.

AU - Levin, M.D.

AU - Broijl, A.

AU - Bos, G.M.J.

AU - Kersten, M.J.

AU - Mutis, T.

AU - Verkleij, C.P.M.

AU - Nijhof, I.S.

AU - Maas-Bosman, P.W.C.

AU - Klein, S.K.

AU - Zweegman, S.

AU - Sonneveld, P.

AU - van de Donk, N.W.C.J.

PY - 2021/12/14

Y1 - 2021/12/14

KW - CD38 EXPRESSION

KW - OPEN-LABEL

KW - INTRAVENOUS DARATUMUMAB

KW - UP-REGULATION

KW - CELLS

KW - DEXAMETHASONE

KW - LENALIDOMIDE

KW - MONOTHERAPY

KW - BORTEZOMIB

KW - EXPANSION

U2 - 10.1182/bloodadvances.2021005220

DO - 10.1182/bloodadvances.2021005220

M3 - Article

C2 - 34625791

VL - 5

SP - 5128

EP - 5139

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 23

ER -